Klose, Christoph S. N.

Abstract Introduction Penile plication is the gold standard operation for Peyronie’s disease with preserved erectile function but is associated with persistence of hourglass shaft deformity and palpable, permanent plication sutures that may be bothersome in some patients. A novel technique utilizing extratunical grafting overlying plication sutures in the tunica albuginea may improve patient discomfort, increase penile girth, and improve overall satisfaction. Objective We aim to analyze patient centered outcomes and satisfaction scores associated with this operation. Methods We retrospectively evaluated 13 patients who underwent Peyronie’s correction with penile plication with extratunical onlay grafting with biological Dura substitute graft performed by a single surgeon at a tertiary academic center. The graft was placed over 2-0 Ethibond Lue plication sutures in a circumferential fashion sparing the neurovascular bundle and secured with chromic suture. Primary endpoints of interest were patient satisfaction scores (1-10), presence of hourglass, palpability of sutures as well as associated discomfort, and sexual activity. Results Median follow up was 15.4 months. 100% of patient were sexually active at time of follow up. Mean patient reported post operative satisfaction was 8.9 out of 10. No patients endorsed palpability of plication sutures, coital discomfort at site of repair, or persistence of hourglass or concavity deformity. In patients who reported less than a 10 in satisfaction, areas of dissatisfaction include persistence of curvature, albeit decreased pre-operatively, as well as enhanced girth associated with dyspareunia of the receptive partner during intercourse in a single patient. Conclusions We present excellent post operative satisfaction and patient centered outcomes utilizing extratunical grafting overlying penile plication sutures in Peyronie’s disease repair. This novel technique may meaningfully improve patient satisfaction is patients with Peyronie’s disease undergoing plication alone. Disclosure No

Abstract Introduction Vasectomy is a highly effective, permanent method of contraception. Vasectomy is commonly performed in the outpatient urology clinic with the patient awake. There is clearly anticipation of pain as well as anxiety associated with the procedure. Objective The objective of our study was to evaluate anticipated versus experienced pain associated with office-based vasectomy. Methods We studied men who underwent vasectomy in May and June of 2022. Men who had no history of scrotal surgery of any kind were asked to score the anticipated pain associated with an office based vasectomy with a score of 0-10. After the vasectomy, patients were asked to rate the pain they perceived with the vasectomy on the same scale (0-10). Results A total of 17 men were asked to rate their pain as discussed in the method section. The median age of men sampled was 38 years of age. All men we treated were given 15 mg of Valium before the procedure and instructed to take the medication 30 minutes prior to their procedure. The average pre vasectomy prediction pain score was 7.5+/- 1.9; the average post-injection perceived pain score was 2.9+/- 1.9. Thus there was an average decrease of over 4 points in the predicted pain versus perceived pain. A two-sample T test was performed; in addition Wilcoxson Signed Rank Test was performed. Both tests showed a statistical significance in the difference between pre and post vasectomy pain scores (p<0.001). Conclusions We found that patients who are undergoing office based vasectomy for the first time have a significantly higher perception of pain versus perception of pain after the injection. We have utilized this data in our clinic to explain to patients that while most patients will predict a high pain score associated with the vasectomy, the vast majority of patients report minimal pain after the procedure. Our study can be particularly helpful in patients who have had significant anxiety about office based vasectomy and for those patients who are deciding between office based vasectomy and vasectomy performed under general anesthesia. Disclosure No

Abstract Introduction Introduction: Peyronie’s disease (PD) is a fibrosing condition of the tunica albuginea characterized by a palpable plaque with varying impacts on the patient’s erection: curvature, shortening, indentations, hinging, and narrowing. Stepwise intralesional injection of collagenase clostridium histolyticum (CCH) is the only FDA approved medical treatment for PD. We retrospectively reviewed Xiaflex® treated patients for satisfaction with therapy or pursuit of subsequent surgery. Objective Objective: To assess global satisfaction with intralesional Xiaflex based on whether patients subsequently elected surgery. Methods Methods: This is a retrospective review of patients presenting with PD to a single center and managed by a single provider from 2020-2024 with six-month follow-up post-treatment. Patient presentations were recorded in an Institutional Review Board approved database. Data storage and analytics were conducted using REDCap. Results Results: The cohort for this study was 159 men treated with intralesional Xiaflex. 18 of the 159 were excluded from analysis due to ongoing treatment. 48.9% of patients (69/141) were satisfied with CCH outcomes and sought no further therapy. 51.1% of patients (72/141) were not satisfied with their outcomes. Of the patients not satisfied with treatment, 48/72 (66.7%) elected subsequent surgical interventions: 18 penile plications, 8 incision and grafting and 22 inflatable penile prostheses. 51.7% (73/141) of patients completed (8) CCH treatments. Among the 73 men who had a complete set of CCH injections, 24.6% (18/73) elected subsequent surgery. Among the patients who had fewer than 8 treatments 46.9% (30/64) elected surgery following Xiaflex. Conclusions Conclusion: If successful medical management of Peyronie’s disease is defined by men who decline subsequent surgical interventions, Xiaflex® was highly successful 75% (55/73). Patients who have Peyronie’s disease are highly motivated and will pursue surgical interventions following a trial of CCH. Disclosure No